Stephen Anthony
Overview
Explore the profile of Stephen Anthony including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
377
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeidner J, Lin T, Vigil C, Fine G, Yair Levy M, Nazha A, et al.
Blood Cancer J
. 2021 Oct;
11(10):175.
PMID: 34718324
No abstract available.
2.
Brown J, Plummer R, Bauer T, Anthony S, Sarantopoulos J, de Vos F, et al.
Exp Hematol Oncol
. 2017 Oct;
6:27.
PMID: 29026685
Background: Carfilzomib is approved in the United States and Europe for treatment of relapsed or refractory multiple myeloma (MM). This study evaluated pharmacokinetics (PK) and safety of carfilzomib in patients...
3.
Anthony S, Carroll-Portillo A, Timlin J
Methods Mol Biol
. 2015 Nov;
1346:185-207.
PMID: 26542723
Total internal reflection fluorescence (TIRF) microscopy is a powerful technique for interrogating protein dynamics in the membranes of living single cells. Receptor-ligand interactions are of particular interest for improving our...
4.
Borad M, Babiker H, Anthony S, Mita M, Buchbinder A, Keilani T, et al.
Cancer Invest
. 2015 Apr;
33(5):172-9.
PMID: 25844818
Purpose: To evaluate the maximum tolerated dose, safety profile, pharmacokinetics, and pharmacodynamics of pegaspargase (PEG-ASP) in combination with gemcitabine in patients with advanced metastatic solid tumors and lymphoma. Methods: We...
5.
Chai K, Anthony S, Coiera E, Magrabi F
J Am Med Inform Assoc
. 2013 May;
20(5):980-5.
PMID: 23666777
Objective: To examine the feasibility of using statistical text classification to automatically identify health information technology (HIT) incidents in the USA Food and Drug Administration (FDA) Manufacturer and User Facility...
6.
Jameson G, Hamm J, Weiss G, Alemany C, Anthony S, Basche M, et al.
Clin Cancer Res
. 2012 Nov;
19(1):268-78.
PMID: 23136196
Purpose: This study was designed to establish the maximum tolerated dose (MTD) and to evaluate tolerability, pharmacokinetics, and antitumor activity of etirinotecan pegol. Experimental Design: Patients with refractory solid malignancies...
7.
Lin F, Anthony S, Polasek T, Tsafnat G, Doogue M
BMC Bioinformatics
. 2011 Apr;
12:112.
PMID: 21510898
Background: The identification of drug characteristics is a clinically important task, but it requires much expert knowledge and consumes substantial resources. We have developed a statistical text-mining approach (BInary Characteristics...
8.
Von Hoff D, Stephenson Jr J, Rosen P, Loesch D, Borad M, Anthony S, et al.
J Clin Oncol
. 2010 Oct;
28(33):4877-83.
PMID: 20921468
Purpose: To compare the progression-free survival (PFS) using a treatment regimen selected by molecular profiling (MP) of a patient's tumor with the PFS for the most recent regimen on which...
9.
Sintchenko V, Anthony S, Phan X, Lin F, Coiera E
PLoS One
. 2010 Mar;
5(3):e9535.
PMID: 20224767
Background: Computational discovery is playing an ever-greater role in supporting the processes of knowledge synthesis. A significant proportion of the more than 18 million manuscripts indexed in the PubMed database...
10.
Anthony S, Zhang L, Granick S
Langmuir
. 2006 May;
22(12):5266-72.
PMID: 16732651
Methods are discussed to track single molecules in planar-supported phospholipid bilayers. Mainly, these methods constitute optimizations for a low signal-to-noise ratio and for the dim optical characteristics of single molecules....